Sandoz introduces rivastigmine patch
PRINCETON, N.J. — Sandoz on Wednesday introduced rivastigmine transdermal system, a generic version of Exelon Patch1, in the United States.
The rivastigmine patch is used to treat mild, moderate and severe memory problems associated with both Alzheimer’s disease and Parkinson’s disease.
"Sandoz is pleased to make rivastigmine patch available as a generic option for patients with memory problems associated with Alzheimer’s disease,” Sandoz president Peter Goldschmidt said. “Rivastigmine has been studied for more than a decade in clinical trials and is the only Alzheimer's disease treatment that comes in the form of a patch with the medication absorbed through the skin.”
For the 12 months ending in June, U.S. sales for the rivastigmine patch were $646 million, according to the company. Sandoz will sell rivastigmine in 13.3 mg strength, the same strength as the brand.
Sam’s Club to offer free diabetes screenings
BENTONVILLE, Ark. — Sam’s Club on Wednesday announced that it will provide a fifth year of free diabetes screenings for the public.
Nearly 28% of adults in the United States don’t know that they have it, while 90% of adults with prediabetes remain undiagnosed, according to Sundial.
The screenings, which are valued at $250, are confidential and available at all Sam’s Club locations with a pharmacy on Sept. 12 from 11 a.m. to 3 p.m. They include tests for:
- A1C, to measure your average blood sugar level over the past three months;
- Glucose, to measure the current amount of sugar in your blood;
- Blood pressure;
- Total cholesterol;
- HDL (good cholesterol);
- Risk ratio; and
- Body mass index.
Par launches generic AndroGel
CHESTNUT RIDGE, N.Y. — Par Pharmaceutical on Wednesday announced that it has begun shipping its generic version of AbbVie’s AnroGel (testosterone gel 1%) in 2.5-g and 5-g foil packets, which contain 25- and 50-mg of testosterone, respectively. Par recently received approval from the Food and Drug Administration for the generic, five years ahead of the expiration of the relevant patent, Par said
The drug is used for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, the company said. Annual U.S. sales of testosterone gel 1% packets are approximately $206 million, according to the company.